lyLMP-1-mediated disruption of LMP-1 oligomers. Modulation of LMP-1-activated signaling pathways is the first identified biological activity associated with lyLMP-1, and this activity may contribute to the progression of EBV's lytic cycle.
Epstein-Barr virus (EBV), a ubiquitous human herpesvirus causally associated with several human tumors (23) , infects resting B cells and establishes a latent infection resulting in unlimited proliferation. Latent membrane protein-1 (LMP-1) is an essential viral membrane protein required for immortalization by EBV and acts by regulating key cell signaling pathways. Although EBV-infected B cells rarely enter the lytic cycle and release virus (24, 30, 33) , certain EBV-positive B-cell lines can be induced to release infectious progeny through treatment with agents such as tetradecanoyl phorbol acetate (TPA) and sodium butyrate (10, 34, 35) . Lytic cycle entry results in temporally regulated expression of the majority of the viral genome (ϳ100 open reading frames [ORFs]) (2, 32) .
One late lytic cycle promoter, EDL1A, lies within the LMP-1 gene and drives the expression of a transcript encoding a predicted ORF corresponding to an amino-terminally truncated form of LMP-1 (11) . A protein in infected cells of molecular weight predicted by this ORF has been termed lytic LMP-1 (lyLMP-1) because of its expression during EBV's lytic cycle (1, 3, 7, 11, 29) . The lyLMP-1 ORF begins at methionine 129 of the LMP-1 sequence and continues through the fifth and sixth transmembrane domains and entire carboxy terminus. lyLMP-1 shares none of LMP-1's known biological or biochemical properties (19, 31) , and little is known about lyLMP-1's function in the infected cell. We reported previously that lyLMP-1 is a component of the EBV virion and proposed a function in the initial stages of infection and/or during the lytic cycle (7) . Its sequence identity with LMP-1 suggests that lyLMP-1 may interact with LMP-1 itself or with effectors of LMP-1 signaling. We have begun to characterize the biochemical and biological properties of lyLMP-1, with the goal of understanding its role in the virus life cycle, and have tested the hypothesis that lyLMP-1 affects the ability of full-length LMP-1 to activate cell signaling pathways.
De novo synthesis of lyLMP-1 in TPA-and butyrate-induced B95-8 cells. Western blot analysis of permissive EBV-positive B-cell lines induced to enter the lytic cycle often reveals a ladder of LMP-1-immunoreactive proteins migrating with lower apparent molecular weights than does LMP-1. Detection of this LMP-1 ladder of bands depends upon the amount of LMP-1 expressed in the cell (reference 7 and unpublished observations). Whether these LMP-1-related proteins are derived from proteolysis of LMP-1 (before or after cell lysis) or from de novo translation initiating at internal methionines in the LMP-1 ORF has been difficult to ascertain (18) . The 45-kDa LMP-1-immunoreactive protein, detected in induced cells, migrates with a molecular mass consistent with that reported for the migration of lyLMP-1 (1, 7) as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
To confirm that the 45-kDa lyLMP-1 protein arises from de novo translation of the EDL1A transcript, we asked if a precursor-product relationship existed between LMP-1 and the 45-kDa protein. B95-8 cells were cultured in 20 ng of TPA per ml and 3.5 mM sodium butyrate for 48 h and starved in methionine-free medium for 1 h, and then 1 mCi of Tran [ 35 S]methionine (ICN) per ml was added for an additional 20 min. Following the pulse, cells were grown in RPMI 1640-10% calf serum for up to 20 h. Cell pellets were solubilized in 5ϫ radioimmunoprecipitation assay [RIPA] buffer (100 mM Tris [pH 8.0], 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% deoxycholate) and sonicated, and LMP-1 proteins were immunoprecipitated as described previously (21) . Boiled samples were precleared with protein G-agarose beads (Boehringer Mannheim), incubated with polyclonal LMP-1 antiserum, and precipitated with protein G-agarose beads. The LMP-1 antiserum was raised in rabbits against an LMP-1 carboxy terminusglutathione S-transferase fusion protein. Immunoprecipitates were resolved by SDS-PAGE and analyzed by autoradiography ( Fig. 1 ). If the 45-kDa lyLMP-1 protein arises de novo from its own transcript, then it should be detectable by autoradiography in cells labeled with [ 35 S]methionine for short periods without subsequent chase. [ 35 S]methionine-labeled 45-kDa lyLMP-1 was readily detectable after the 30-min pulse and persisted, with a calculated half-life of at least 20 h ( Fig. 1) . In contrast to lyLMP-1, 35 S-labeled LMP-1 decreased over time and was undetectable 20 h following the pulse. Consistent with its reported rapid turnover in other cells (1, 20, 21) , the halflife of LMP-1 in TPA-and butyrate-treated B95-8 cells was between 3 and 6 h. It is unlikely that radiolabeled lyLMP-1 results from LMP-1 degradation since a band comigrating with lyLMP-1 was not seen in 35 S-labeled uninduced B95-8 cells, which express primarily LMP-1 (not shown). Also, unlike the relationship between the loss of LMP-1 and the appearance of the ϳ40-kDa LMP-1 immunoreactive protein, there was no precursor-product relationship between LMP-1 and the 45-kDa lyLMP-1 protein (Fig. 1) . These results provide experimental evidence for lyLMP-1's de novo translation from the EDL1A transcript in induced B95-8 cells. The difference in half-lives of the two LMP-1 proteins suggests distinct turnover mechanisms and is consistent with previous results demonstrating a correlation between LMP-1's biological activity and rapid turnover (21) . The long half-life of lyLMP-1 is consistent with our observation that, once carried into the infected cell with the virion, the protein remains detectable for ϳ48 h, in the absence of de novo protein synthesis (7) . The persistence of lyLMP-1 protein in the cell early after infection may be important for regulation of cellular signaling pathways involved in establishment of immortalization.
Inhibition of LMP-1-stimulated NF-B activity by lyLMP-1. The high levels of lyLMP-1 expressed during lytic cycle progression in EBV-infected cells may affect the function of LMP-1 and thereby contribute to the disruption of latency. Expression of LMP-1 in certain cell lines results in upregulation of NF-B activity (20-to 50-fold) (9, 12, 26) . Tumor necrosis factor receptor-associated factor (TRAF) binding to LMP-1's carboxy terminus is required for NF-B activation (4, 14) , and LMP-1 oligomerization is proposed to be required for both TRAF binding and NF-B activation (8, 27) . To determine whether expression of lyLMP-1 could affect LMP-1 activity, we coexpressed the two proteins in the human embryonic kidney cell line 293 and assayed for NF-B activity (Fig.  2) . 293 cells were electroporated (Bio-Rad Gene Pulser) with a luciferase reporter driven by the minimal fos promoter con- taining three upstream B binding sites (p1242 [26] ), pRSV-lacZ, and a constant amount of pCMV-LMP-1, together with increasing amounts of pCMV-lyLMP-1. pCMV-lyLMP-1 and pCMV-LMP-1 are pCDNA3-based expression vectors encoding the lyLMP-1 and LMP-1 ORFs, respectively, under the control of the cytomegalovirus promoter. Consistent with previous results, lyLMP-1 was deficient, relative to LMP-1, in its ability to activate NF-B ( Fig. 2A and C) (12, 26) . Coexpression of lyLMP-1 and LMP-1 resulted in the inhibition of LMP-1-stimulated NF-B activity. Maximal inhibition (ϳ90%) of LMP-1-stimulated NF-B activity by lyLMP-1 occurred when there was an ϳ18-fold excess of input pCMV-lyLMP-1 relative to the input pCMV-LMP-1 ( Fig. 2A and C) . This ratio of input DNA resulted in approximately equivalent expression levels of the two LMP-1 proteins (Fig. 2B) . LMP-1-stimulated NF-B activity was inhibited dose dependently by coexpression of lyLMP-1 (Fig. 2C) . These results demonstrate that lyLMP-1 can negatively regulate LMP-1 signaling in 293 cells. Consistent with lyLMP-1's potential to negatively regulate LMP-1 signaling in virus-infected cells is the finding that the ratio of lyLMP-1 to LMP-1 required to block LMP-1 signaling in 293 cells (Fig. 2B) is roughly equivalent to the ratio of LMP-1 proteins in induced B95-8 cells (1, 7) .
LyLMP-1 does not disrupt LMP-1 oligomerization. LMP-1 is believed to activate signaling pathways as a constitutive TRAF-binding oligomer (4, 5, 13) . Overexpression of lyLMP-1 (relative to the level of LMP-1) may interfere with LMP-1 signaling by disrupting LMP-1 oligomerization. High levels of lyLMP-1 may inhibit LMP-1 oligomerization by associating with LMP-1 and preventing formation of full-length LMP-1 oligomers. To explore the mechanism by which lyLMP-1 inhibits LMP-1 signaling, we determined if lyLMP-1 either oligomerizes with LMP-1 or alters LMP-1's ability to homo-oligomerize. To assess if lyLMP-1 associates with LMP-1, pCMV-lyLMP-1 and pCMV-LMP-1myc were cotransfected into 293 cells and 48 h later cell extracts prepared as described by Gires et al. (8) were assayed for oligomerization by coimmunoprecipitation with the anti-myc monoclonal antibody 9E10 (Santa Cruz Biochemicals) ( Fig. 3) . pCMV-LMP-1myc was constructed from pCMV-LMP-1 by insertion of the myc epitope tag (EQKLISEEDL) at LMP-1's carboxy terminus. pCMV-C⌬55 is an expression vector encoding a mutant LMP-1 lacking the last carboxy-terminal 55 amino acids and has been described previously (22) . The NP-40 soluble fraction was precleared with protein G-agarose beads, and LMP-1 myc was immunoprecipitated from the precleared supernatant with anti-myc antibody (9E10; Santa Cruz). Complexes were recovered by incubation with protein G-agarose beads, washed with 1ϫ RIPA buffer, resuspended in 4ϫ SDS sample buffer, and analyzed by SDS-PAGE and Western blotting. lyLMP-1 was not detectable in LMP-1 myc immunoprecipitates, despite the large (Ն5-fold) excess of lyLMP-1 protein relative to the level of LMP-1 myc protein (Fig. 3, lane 5) . The inability of lyLMP-1 to coimmunoprecipitate with LMP-1 myc was not due to immunoprecipitation conditions or to the presence of the myc epitope tag at LMP-1's carboxy terminus since C⌬55, a mutant LMP-1 lacking the last carboxy-terminal 55 amino acids, interacted efficiently with LMP-1 myc (Fig. 3, lane 10) . These results are consistent with the work of Gires et al., demonstrating a role for the amino terminus and transmembrane domains of LMP-1 in oligomerization (8) . Importantly, C⌬55 was detected in LMP-1 myc immunoprecipitates from cells coexpressing LMP-1 myc and lyLMP-1, indicating that lyLMP-1 did not interfere with LMP-1's ability to oligomerize (Fig. 3, lane 12) . These results demonstrate that lyLMP-1 does not associate with LMP-1 and that it does not prevent LMP-1 from forming homo-oligomers. It is unlikely, therefore, that lyLMP-1 inhibits LMP-1 signaling via disruption of LMP-1 oligomerization.
Immortalization of human B cells by EBV is complex and results from the expression of several viral gene products, one of which is LMP-1. Since expression of LMP-1 proteins is restricted to full-length LMP-1 in latently infected lymphoblastoid cell lines, we think it unlikely that lyLMP-1 plays a role in the maintenance of immortalization. This conclusion is supported by the observation that lymphoblastoid cell lines infected with recombinant EBV and expressing LMP-1 proliferate despite the presence in these cells of LMP-1 immunoreactive, smaller-molecular-weight proteins (15) . LMP-1 can activate divergent signaling pathways (6, 16, 17, 25) . Not all LMP-1-activated pathways are likely to be required for immortalization (16, 28) , and overexpression of lyLMP-1 may not regulate all LMP-1-activated signaling.
The high level of expression of lyLMP-1 in virus-producing cells suggests a function during the lytic cycle, and the presence of lyLMP-1 protein in the EBV virion suggests a role shortly after infection. lyLMP-1 can negatively affect LMP-1 function in 293 cells without disrupting LMP-1 oligomerization. These observations are consistent with a model in which the lyLMP-1 protein may downregulate NF-B activation in the late stages of lytic infection by negatively affecting the function of LMP-1. In addition, lyLMP-1 has the potential to regulate signaling in infected cells in an LMP-1-independent manner, i.e., upon virus entry prior to LMP-1 expression (7) . Studies are in progress to determine the mechanism by which lyLMP-1 affects LMP-1-regulated pathways and to identify the role of lyLMP-1 in EBV's life cycle.
